Azitra, Inc. to Showcase at Biotech Event with J.P. Morgan Conference

Azitra, Inc. Takes Center Stage at the Biotech Showcase 2026

Introduction
Azitra, Inc., recognized by its ticker symbol AZTR on NYSE American, is gearing up for a notable presence at the upcoming Biotech Showcase, running from January 12 to 14, 2026, in San Francisco. As a clinical stage biopharmaceutical company, Azitra specializes in pioneering therapies aimed at precision dermatology. This event is particularly significant as it coincides with the esteemed J.P. Morgan Annual Healthcare Conference, providing Azitra a unique platform to connect with investors and industry leaders.

Showcasing Innovations
Azitra’s team, led by Chief Operating Officer Travis Whitfill, will be presenting on January 13, 2026, at 2:30 PM PT at Hilton San Francisco Union Square. The company plans to engage in one-on-one discussions with registered investors and potential partners, highlighting its clinical development strategies and recent achievements in the biopharmaceutical landscape.

Leading Programs and Clinical Trials
Azitra's commitment to innovative solutions is exemplified through its lead program, ATR-12. This initiative employs an engineered strain of S. epidermidis, designed specifically to address Netherton syndrome, a rare and chronic skin condition lacking approved treatment options. The company is currently advancing toward a Phase 1b clinical trial focusing on adult patients with this condition. Additionally, Azitra is working on ATR-04, which utilizes another engineered strain of S. epidermidis targeting EGFR inhibitor-associated skin toxicity. With approximately 150,000 patients affected by skin rashes due to EGFR inhibitors in the U.S., the company’s endeavors here are crucial. ATR-04 has also been granted Fast Track designation by the FDA, underscoring its promise in the clinical field.

Technological Integration
What sets Azitra apart is the integration of cutting-edge technology with their proprietary platform, which encompasses a vast microbial library containing around 1,500 bacterial strains. This library serves as a foundation for developing their therapeutic products, augmented by artificial intelligence and machine learning technologies. These innovations help to efficiently screen strains for potential drug candidates, revolutionizing the development process in biotechnology.

Looking Forward
As Azitra prepares for this pivotal showcase, the company remains focused on its trajectory of growth and the advancement of its clinical programs. With significant milestones ahead, the presentation at the Biotech Showcase stands as an opportunity not only to demonstrate their significant strides in dermatological therapy development but also to foster valuable connections within the healthcare investment community.

Conclusion
Azitra's participation in the Biotech Showcase represents not merely a networking event but a celebration of innovation in healthcare biotechnology. As the company endeavors to change the landscape of treatment for chronic skin diseases, the insights shared during this conference could pave the way for future partnerships and collaborations, crucial to further their mission of offering life-altering therapies to patients in need.